Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma

27 Jul 2020

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32719501
DOI: 10.1038/s41409-020-01006-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphomaPMID 32719501Read ↗

CAR-T Cell TherapySemantic proximity Read ↗

CAR T-Cell Therapy in Large B-Cell LymphomaSemantic proximity Read ↗

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell TherapySemantic proximity Read ↗

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST studySemantic proximity Read ↗

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapseSemantic proximity Read ↗

Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphomaSemantic proximity Read ↗

"RT or not RT?" The question for early-stage peripheral T-cell lymphoma.Semantic proximity Read ↗

Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphomaSemantic proximity Read ↗

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.Semantic proximity Read ↗

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.